On July 2, Sino Biopharmaceutical rose 4.99% in regular trading, trading at HK$4.67/share, with turnover of HK$174 million.

The pharmaceutical sector rallied broadly, with CSPC Pharma up 9.47%, Hansoh Pharma up 7.49%, United Lab up 8.07%, and Hengrui Pharma up 3.72%, providing strong sector tailwinds. On the news front, multiple positive catalysts have converged in recent weeks. On June 29, embodied intelligence company Zhipingfang announced completion of a nearly RMB 5 billion financing round with a valuation exceeding RMB 20 billion, in which Sino Biopharmaceutical participated as an industrial investor. The market views this as a strategic signal of the company exploring growth beyond its core pharmaceutical business.

Additionally, the company recently announced a HK$2 billion share buyback plan, obtained marketing approval for Peceleganan Spray for wound infections, had its new drug application for tecotabart vedotin (LM-302) accepted for gastric cancer treatment, and presented multiple clinical datasets at ASCO including its landmark lung cancer combination therapy results.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)